medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2006, Number 1

<< Back Next >>

Rev Mex Oftalmol 2006; 80 (1)

Estudio clínico comparativo del diclofenaco vs ketorolaco en el manejo sintomático de las conjuntivitis alérgicas en niños

González JR, Baiza-Durán LM, Núñez-Adame RM, González-Cervantes CP

Language: Spanish
References: 24
Page: 16-20
PDF size: 167.53 Kb.


ABSTRACT

Purpose. To compare safety and efficacy of 0.1% sodium diclofenac ophthalmic solution and 0.05% ketorolac tromethamine ophthalmic solution for the treatment of mild to moderated allergic conjunctivitis in pediatric population.
Material and methods. A prospective, descriptive, double blind and longitudinal clinical study was realized. We included 116 eyes from 58 patients, between 5 and 17 years of age, with diagnosis of mild to moderated allergic conjunctivitis. Each one applied in a randomized way 0.1% sodium diclofenac or 0.05% ketorolac tromethamine ophthalmic solutions four times a day during 60 days. Safety, tolerance and efficacy clinical parameters were evaluated during days 2, 7, 14, 30 and 60.
Results. Patients who received 0.1% sodium diclofenac ophthalmic solution showed an improvement of allergic conjunctivitis clinical manifestations similar to those on 0.05% ketorolac tromethamine ophthalmic solution.
Conclusions. 0.1% sodium diclofenac ophthalmic solution application shown efficacy as well as tolerance, similar to 0.05% ketorolac tromethamine ophthalmic solution for allergic conjunctivitis symptoms management.


REFERENCES

  1. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: inmunologic mechanisms and current approches to therapy. Surv Ophthalmol 1993; 38 (Suppl):115 - 132.

  2. Laibovitz R, Koester L, Reaves T. Safety and efficacy of diclofenaco sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis. J Ocular Pharm Ther 1995; 11:361-368.

  3. Seamone CD, Jackson WB. Immunology of the external eye. En: Tasman W, Jaeger EA (eds.). Duane’s Clinical Ophthalmology. Philadelphia, Lippincott-Raven, 1995; Vol. 4, Chap 2.

  4. Stock EL, Pendleton RB. Pharmacological treatment of ocular allergic diseases. En: International Ophthalmology Clinics: Pharmacology. Boston, Little Brown and Company 1993; 33 (4):47-58.

  5. Graue E. Conjuntivitis. En: Graue E (ed.). Oftalmología en la práctica de la medicina general. México, Interamericana-McGraw-Hill, 1995; 79-92.

  6. Verulet D, Vellieux P, Charpin J. Potentiation of cutaneous reactivity and blood leukocyte histamine realease by deuterium oxide in human beings. Acta Allergol 1976; 31:367-372.

  7. Lichtenstein LM. Sequential analysis of the allergic response. Int Arch Allergy Appl Immunol 1975; 49:143-154.

  8. Male D, Champion B, Cooke A y col. Cytokines. En: Advanced immunology. New York, Gower, 1991; 11.1-11.17.

  9. Dhir SP, Garg SK, Sharma YR, Lath NK. Prostaglandins in human tears. Am J Ophthalmol 1979; 87:403-404.

  10. Bisgaard H, Ford-Hutchinson AW, Charleson S, Tauderf E. Production of leukotrienes in human skin and conjunctival mucosa after specific allergen challenge. Allergy 1985; 40:417-423.

  11. Woodward DF, Ledgard SE. Comparison of leukotrienes as conjunctival microvascular permeability factors. Ophthalmic Res 1985; 17:318-320.

  12. Ciprandi G, Buscaglia S, Cerqueti PM, Canonica GW. Drug treatment of allergic conjuctivitis: a review of the evidence. Drugs 1992; 43 (2):154-176.

  13. Jaanus SD, Lesher GA. Anti-inflamatory drugs. En: Barlett JD, Jaanus SD (eds.). Clinical ocular pharmacology. Newton, Butterwoth-Heinemann, 1995; 303-335.

  14. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992; 36:259-284.

  15. Anon. Diclofenac. Med Lett Drugs Ther 1988; 30:109-11.

  16. De Menezes MRD, Catanzaro-Guimaraes SA. Determination of anti-inflammatory and antimitotic activities of non-steroid anti-inflammatory drugs ibuprofen, diclofenac sodium and fentiazac. Cell Mol Biol 1985; 31:455-61.

  17. Ku EC, Lee W, Kothari HV y col. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med 1986; 80(Suppl 4B):18-23.

  18. Vane J, Botting R. Mechanism of action of nonsteroidal antiinflammatory drugs. Am J Med 1998; 104:2S-8S.

  19. Cryer B, Dubois A. The advent of highly selective inhibitors of cyclooxygenase—a review. Prostaglandins Other Lipid Mediators 1998; 56:341-61.

  20. Toda I, Fujishima H, Tsubota K. Ocular fatigue is the major symptom of dry eye. Acta Ophthalmol 1993; 71:347-352.

  21. Norn MS. Diagnóstico del ojo seco. En: Lemp MA, Marquardt R (eds.). El ojo seco. Barcelona, Springer-Verlag Ibérica, 1994; 139-144.

  22. Ballas Z, Blumenthal M, Tinkelman DG. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993; 38(Sup):141-8.

  23. Tinkelman DG, Rupp G, Kaufman H. Double-masked, pairedcomparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993; 38(Sup):133-40.

  24. Tauber J, Abelson M, Ostrov C y col. A multicenter comparison of diclofenac sodium 0.1% to ketorolac tromethamine 0.5% in patients with acute seasonal allergic conjuctivitis. Inves Ophthalmol Vis Sci 1994; 35(Sup):1291.




2020     |     www.medigraphic.com